BAT1706 vs Bevacizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

Bevacizumab

Marketed by Roche

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT00806923 · Phase 3 · completed

This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: November 2026 · NCT04958811 (registry estimate)

Reported efficacy

Progression-free survival (Event driven): Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo (met)

Result source: NCT00806923

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1706Bevacizumab
PFS, median—Not posted · NCT033299114.8 vs 3.7+1.1 vs placebon 370NCT00257608
17 other results
OS, median—Not posted · NCT033299119.3 vs 9.2+0.1 vs placebon 319NCT00130728
20 other results
ORR—Not posted · NCT0332991147.6% vs 42.8%vs Bevacizumab (Avastin)wk 24 · n 379NCT02754882
9 other results
  • 40.3% vs 44.6% wk 18 · n 315 · Phase 3 · primary NCT03296163
  • 44.3% vs 46.4% wk 18 · n 221 · Phase 3 · primary NCT02954172
  • 51.6% vs 53.7% n 364 · Phase 3 · primary NCT02810457
  • 12.6% vs 6.2% n 301 · Phase 3 · secondary NCT00130728
  • 47.8% vs 51% wk 19 · n 364 · Phase 3 · secondary NCT02810457
  • 8.6% vs 6.3% n 245 · Phase 3 · secondary NCT01351415
  • 34.1% vs 33% n 472 · Phase 3 · secondary NCT00762034
  • 18.2% n 22 · Phase 2 · primary NCT04426825
  • 17.4% n 23 · Phase 2 · secondary NCT04426825
Duration of response, median—Not posted · NCT033299119.7 vs 8.4+1.3 vs placebon 38NCT00130728
4 other results

PFS, median

BAT1706
—Not posted · NCT03329911
Bevacizumab
4.8 vs 3.7+1.1 vs placebon 370NCT00257608
17 other results

OS, median

BAT1706
—Not posted · NCT03329911
Bevacizumab
9.3 vs 9.2+0.1 vs placebon 319NCT00130728
20 other results

ORR

BAT1706
—Not posted · NCT03329911
Bevacizumab
47.6% vs 42.8%vs Bevacizumab (Avastin)wk 24 · n 379NCT02754882
9 other results
  • 40.3% vs 44.6% wk 18 · n 315 · Phase 3 · primary NCT03296163
  • 44.3% vs 46.4% wk 18 · n 221 · Phase 3 · primary NCT02954172
  • 51.6% vs 53.7% n 364 · Phase 3 · primary NCT02810457
  • 12.6% vs 6.2% n 301 · Phase 3 · secondary NCT00130728
  • 47.8% vs 51% wk 19 · n 364 · Phase 3 · secondary NCT02810457
  • 8.6% vs 6.3% n 245 · Phase 3 · secondary NCT01351415
  • 34.1% vs 33% n 472 · Phase 3 · secondary NCT00762034
  • 18.2% n 22 · Phase 2 · primary NCT04426825
  • 17.4% n 23 · Phase 2 · secondary NCT04426825

Duration of response, median

BAT1706
—Not posted · NCT03329911
Bevacizumab
9.7 vs 8.4+1.3 vs placebon 38NCT00130728
4 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT1706: 3 of 4 rows · Bevacizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBAT1706Bevacizumab
Dropout rate
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
99.4%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
64.2%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
89.8%
NCT02810457 · Phase 3 · registry result, not featured evidence
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
34.3%
NCT03296163 · Phase 3 · registry result, not featured evidence
82.1%
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
1.3%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
90.8%
NCT02754882 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
37.7%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
31.9%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
27.9%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
—Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
64.9%Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
65.4%Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
0%Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
0%Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
100%10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
100%5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
100%0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—
NCT00828009 · Phase 2 · registry result, not featured evidence
—
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
22.9%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
27%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT02810457 · Phase 3 · registry result, not featured evidence
—Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03296163 · Phase 3 · registry result, not featured evidence
—
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
—
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
—
NCT02754882 · Phase 3 · registry result, not featured evidence
—
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
12.6%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
16.2%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
—
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
—Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
—Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
—Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
—
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
—Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
—10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
—5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
—0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
—
NCT00828009 · Phase 2 · registry result, not featured evidence
—
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
—
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
—
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
37.7%a
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 31 more results
76.6%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
25.1%
NCT02810457 · Phase 3 · registry result, not featured evidence
42.5%Arm A (Atezo+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
48.3%Arm B (Atezo+Bev+CP)
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
18.6%
NCT03296163 · Phase 3 · registry result, not featured evidence
46.6%
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
33.5%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
19.8%
NCT02754882 · Phase 3 · registry result, not featured evidence
51.9%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
42.5%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
23.4%
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
6.7%Bevacizumab + Pemetrexed
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
5.2%Bevacizumab + Pemetrexed + Carbopl
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
—Bevacizumab +Pemetrexed Maintenanc
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
21.7%Maintenance Treatment Arm A
NCT00961415 · Phase 3 · registry result, not featured evidence
33.6%Maintenance Treatment Arm B
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
35.1%Osimertinib Alone
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
43.4%Osimertinib Plus Bevacizumab
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
17.4%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
26.7%Arm A (Erlotinib Hydrochloride)
NCT01532089 · Phase 2 · registry result, not featured evidence
39.5%Arm B (Erlotinib Hydrochloride, Be
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
100%10 mg/kg + mFOLFOX6 ± Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0%5 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
100%3 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
50%2 mg/kg + mFOLFOX6 + Bevacizumab
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0%0.45 mg/kg
NCT01327612 · Phase 2 · registry result, not featured evidence
33.3%
NCT00828009 · Phase 2 · registry result, not featured evidence
32.5%
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
50%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
69.4%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
a
fatigue 40.4%
nausea 37.4%
haemoglobin decreased 35.6%
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 30 more results
creatinine increased 33.6%
neutrophil count decreased 32.1%
anemia 24.9%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
alopecia 42.5%
neutropenia 30.1%
anaemia 29%
NCT02810457 · Phase 3 · registry result, not featured evidence
alopecia 45%
anaemia 36.5%
nausea 32.5%
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 47.8%
nausea 37.9%
fatigue 34.9%
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3 · registry result, not featured evidence
diarrhoea 64.9% (placebo 51.8%)
rash 61.7% (placebo 58.8%)
fatigue 46.6% (placebo 39.6%)
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
alopecia 48.7%
anaemia 23%
nausea 19.6%
NCT02754882 · Phase 3 · registry result, not featured evidence
diarrhoea 37%
nausea 34.6%
decreased appetite 34.2%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
fatigue 60.6%
nausea 53.4%
constipation 41%
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
rash 55.4% (placebo 18.8%)
diarrhoea 51.1% (placebo 19.6%)
fatigue 34.2% (placebo 24.8%)
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
anaemia 51.3%
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
anaemia 72.4%
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
leucocytopenia 66.7%
NCT01661790 · Phase 3 · registry result, not featured evidence · combination
nausea 60.8%
hypertension 35.8%
asthenia 35%
NCT00961415 · Phase 3 · registry result, not featured evidence
nausea 61.6%
hypertension 44%
fatigue 32%
NCT00961415 · Phase 3 · registry result, not featured evidence · combination
diarrhea 49.4%
fatigue 37.7%
cough 36.4%
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhea 53.9%
proteinuria 48.7%
fatigue 43.4%
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
proteinuria 30.4%
aspartate aminotransferase increased 26.1%
fatigue 26.1%
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
rash acneiform 88.9%
diarrhea 82.2%
hypertension 51.1%
NCT01532089 · Phase 2 · registry result, not featured evidence
rash acneiform 97.7%
diarrhea 88.4%
hypertension 83.7%
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
10 mg/kg + mFOLFOX6 ± Bevacizumab
abdominal pain 66.7%
amylase increased 66.7%
anaemia 66.7%
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
5 mg/kg
back pain 100%
blood creatinine increased 100%
blood phosphorus increased 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
3 mg/kg
hepatic enzyme increased 100%
hepatitis c 100%
oesophageal carcinoma 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
2 mg/kg + mFOLFOX6 + Bevacizumab
diarrhoea 100%
fatigue 100%
neutropenia 100%
NCT01327612 · Phase 2 · registry result, not featured evidence · combination
0.45 mg/kg
chest x-ray abnormal 100%
cough 100%
herpes zoster 100%
NCT01327612 · Phase 2 · registry result, not featured evidence
fatigue 78.8%
anemia 54.5%
peripheral sensory neuropathy 51.5%
NCT00828009 · Phase 2 · registry result, not featured evidence
alopecia 62.5%
fatigue 52.5%
hyperglycemia 52.5%
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
pain 75%
fatigue 68.8%
anorexia 50%
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
fatigue: induction 88.9%
hypertension grade: end of induction 88.9%
anemia: induction 75%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

Bevacizumab

Overall Survival 14.6 months
time to event · months
No placebo or comparator arm
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
show 11 more results
11.6 months @ 183wk
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
14.4 months @ 183wk
NCT00976456 · Phase 3 · registry result, not featured evidence · combination
24 months
NCT03133546 · Phase 2 · registry result, not featured evidence · combination
24.3 months
NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy
14.06 months
NCT04426825 · Phase 2 · registry result, not featured evidence · combination
50.6 months
NCT01532089 · Phase 2 · registry result, not featured evidence
32.4 months
NCT01532089 · Phase 2 · registry result, not featured evidence · combination
42.7 months
NCT00828009 · Phase 2 · registry result, not featured evidence
16.5 months
NCT00271505 · Phase 2 · registry result, not featured evidence · combination
14.8 months
NCT00227019 · Phase 2 · registry result, not featured evidence · combination
25.5 months
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
Time to Progression 7.8 months
time to event · months
No placebo or comparator arm
NCT00451906 · Phase 4 · registry result, not featured evidence · combination
Overall Survival 85.8 vs NA Chemotherapy months
time to event · months
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
14.13 vs 16.95 Avastin months
NCT02810457 · Phase 3 · registry result, not featured evidence
19.2 vs 14.7 Bevacizumab+Paclitaxel+Carboplatin months
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
19 vs 14.7 Bevacizumab+Paclitaxel+Carboplatin months
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
NA vs NA Avastin months @ 52wk
NCT03296163 · Phase 3 · registry result, not featured evidence
9.3 vs 9.2 placebo months
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
18.02 vs NA Bevacizumab months
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
11.86 vs 10.22 Standard of Care months
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
12.55 vs 13.4 Pac/Carbo/Bev months
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
14.4 vs 13.3 placebo months
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
Disease-free Survival 40.6 vs 42.9 Chemotherapy months
time to event · months
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
ORR 51.6% (n=364) vs 53.7% (n=367) Avastin
responder rate · % of participants
NCT02810457 · Phase 3 · registry result, not featured evidence
show 7 more results
47.8% (n=364) vs 51% (n=367) Avastin @ 19wk
NCT02810457 · Phase 3 · registry result, not featured evidence
40.3% (n=315) vs 44.6% (n=312) Avastin @ 18wk
NCT03296163 · Phase 3 · registry result, not featured evidence
12.6% (n=301) vs 6.2% (n=306) placebo
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
44.3% (n=221) vs 46.4% (n=220) Bevacizumab @ 18wk
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
47.6% (n=379) vs 42.8% (n=383) Bevacizumab (Avastin) @ 24wk
NCT02754882 · Phase 3 · registry result, not featured evidence
8.6% (n=245) vs 6.3% (n=240) Standard of Care
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
34.1% (n=472) vs 33% (n=467) Pac/Carbo/Bev
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
PFS 7.72 vs 7.62 Avastin months
time to event · months
NCT02810457 · Phase 3 · registry result, not featured evidence
show 5 more results
8.31 vs 8.61 Avastin months @ 52wk*
NCT03296163 · Phase 3 · registry result, not featured evidence · converted to months from 36 weeks as posted
3.4 vs 1.7 placebo months
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
8.43 vs 8.26 Bevacizumab months
NCT02954172 · Phase 3 · registry result, not featured evidence · combination
6.04 vs 5.55 Pac/Carbo/Bev months
NCT00762034 · Phase 3 · registry result, not featured evidence · combination
4.8 vs 3.7 placebo months
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 6.47 vs 6.31 Avastin months
time to event · months
NCT02810457 · Phase 3 · registry result, not featured evidence
show 2 more results
9.7 vs 8.4 placebo months
NCT00130728 · Phase 3 · registry result, not featured evidence · combination
7.46 vs 6.24 Standard of Care months
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
Disease Control 87.6% (n=364) vs 87.5% (n=367) Avastin
absolute value · percentage points
NCT02810457 · Phase 3 · registry result, not featured evidence
PFS 8.3 vs 6.8 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 19.8 vs 14.9 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
19 vs 15 Bevacizumab+Paclitaxel+Carboplatin months
ITT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 9 vs 5.7 Bevacizumab+Paclitaxel+Carboplatin months
time to event · months
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
ORR 49.3% (n=347) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
responder rate · % of participants
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
63.5% (n=353) vs 48% (n=331) Bevacizumab+Paclitaxel+Carboplatin
ITT-WT Population
NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3

+ 33 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · Bevacizumab's landscape